Life Sciences Archive » July, 2012

Life Sciences - July, 2012

268 articles

• FDA OKs System That Can Sense When Drugs Are Taken
• FDA Announces Biosimilar, Prescription Drug User Fees
• Hikma Beats GSK, Pfizer In Argatroban IP Infringement Row
• Zoll Medical Can't Evade Defibrillator Patent License Suit
• P&G Escapes Claims Of Zinc Poisoning From Denture Cream
• GOP Sens. Question $77M CMS Fraud Prevention Program
• Illumina, Investor Drop Fight Over Poison Pill In Roche Bid
• Grassley Calls For More Probes Of FDA Whistleblower 'Spying'
• Covidien Unit Sues Liberty Mutual For Asbestos Coverage
• Fed. Circ. Blocks Courts From Fixing Overbroad Use Codes
• EU Provides Favorable Turf For Pay-For-Delay Cases
• Apax Sues Endo Over $1.2B Qualitest Deal
• Synthes Sued Over Death Allegedly Tied To Bone Cement Trials
• AstraZeneca Denied Attys' Fees Despite Crestor Patent Win
• Teva Says Genzyme, Ex-Employee Stole Sales Staff
• Genzyme Sues To Stop Generic Leukemia Treatment
• Genzyme Accuses Shire Of Making False Bone Drug Claims
• FDA Releases Medical Device User Fees For 2013
• Doctor Targets Hormone Therapy Co. Over Soured Venture
• Holland & Knight Taps Ex-Kenyon Atty To Lead NY IP Group
• Medicare Denial For Osteoarthritis Device Was OK: 9th Circ.
• Volcano Tentatively Exits Investor Suit Over $27M Payouts
• Q&A With Hodgson Russ' Bethany Trachtenberg
• Classen — A Guide For Post-Prometheus Patent Claims
• Takeaways From Avandia For Medicare Advantage Plans
• Galderma Says Watson Generic Infringes Acne Ointment Patents
• Judge Hands Icahn Ammo In Forest Labs Proxy Battle
• McKesson To Pay $151M To Settle States' Drug Pricing Claims
• Corin, Stryker Bid Adieu To Metal-On-Metal Implant Suit
• Zicam Maker Coughs Up $4.5M to Settle Shareholder Action
• DC Circ. Orders HHS To Justify 12-Year Ban Of Purdue Execs
• FDA Lifts Ban On Dr. Reddy's Drugs From Mexican Plant
• Walgreens, Par Escape Ill. Generic Overcharge Suit
• Ex-Home Diagnostics CEO Says He Didn't Divulge Merger Tips
• Medifast Unit To Fork Over $4M To FTC Over Weight-Loss Ads
• Insurance Exchanges Post-ACA — Questions Remain
• Q&A With Knobbe Martens' Mark Benedict
• Pa. Court Sides With J&J In Risperdal Marketing Suit
• Senate Sends Sequestration Transparency Act To President
• 9th Circ. Opts To Rehear Paraplegic's Medtronic Suit
• GSK's $3B Takeover Of Human Genome Survives 2 Challenges
• FDA Drug Approvals Will Slow In 2012, Report Says
• 8th Circ. Revives Prempro Hormone Suits Against Wyeth
• Terumo Seeks To Beat Sony With $640M Olympus Tie-Up Offer
• RoundTable Rakes In $400M In Aspen Surgical Sale
• Mid Europa Buys 50 Percent Stake In Czech Nutrition Co.
• Nelson V. Matrixx Initiatives — Specificity In Complaints
• 8 Pharma Cos. To Pay $38M For Boosting La. Drug Prices
• US Not Liable For $2M In Ruined HIV Samples: 7th Circ.
• Q&A With Vinson & Elkins' Tracey Davies
• Gray Market Inflating Cost Of Scarce Drugs, Report Says
• University Asks Supreme Court For Rehearing Of ACA Suit
• J&J Unit Says Distributor Tried To Steal 70K Customers
• Bard's Calif. Vaginal Mesh Loss Is No Crystal Ball For MDL
• Docs' Push To Limit Painkiller Prescriptions Faces Long Odds
• Par Pharmaceutical Investor Sues To Halt $1.9B TPG Deal
• Cyberonics' False Claims Cost States $75M: Whistleblower
• Pfizer's Chantix Warning Strong Enough, Judge Says
• CORRECTED: Pfizer Takes Fight Over $142M Neurontin Verdict To 1st Circ.
• Guidant Tells Judge J&J Can't Sue Over Botched $22B Merger
• Human Genome Shareholders Say GSK's $3B Offer Too Low
• EU Finds Lundbeck Pay-For-Delay Deals Blocked Generics
• FDA Says Regulation Doesn't Cause Drug Shortages
• Q&A With Skadden's Jim Elacqua
• Men, Makeup And Drugs
• Calif. County's Drug Disposal Law Headed For Big Pharma Fight
• Travelers Sues Cephalon Over $17M In Actiq Claims
• Almirall, Forest Get EU, FDA Nods For COPD Treatment
• Roche's Accutane Warning Passes Muster In MDL
• Sanofi Warned By FDA Over Conditions In 2 Vaccine Plants
• HHS Skirts Questions On ACA Medicaid Expansion: GOP Govs.
• FDA Staff Backs Broader Use Of Roche Eye Drug
• Blackstone Pours $125M Into NantWorks Biopharmaceutical Arm
• Judge Rules FDA Can Regulate Stem Cell Treatment As Drug
• Novartis Sues Lupin To Protect Diovan Patent
• Q&A With Blake's Jill Lawrie
• 9% Of Employers To Drop Insurance Because Of ACA: Survey
• K-Dur: The Rejection Of 'Scope Of The Patent' Test
• Savient Noteholders Can't Force Receivership, Judge Says
• FDA Must Comply With FOIA Request In Email Spying Suit
• Biovail Puts Up $37.5M To Ditch Wellbutrin Antitrust Case
• J&J Shareholders Sue Over $175M In CEO Compensation
• 9th Circ. Ruling Dooms Pharma Rep OT Suits, Attys Say
• Pharmacies Challenge CMS' Diabetic Supply Payment Change
• Pa. Court Affirms $10M Prempro Judgment Against Pfizer
• Alcon Sues Apotex To Block Vigamox Generic
• FDA Wrongly Approved Generic Vancocin, ViroPharma Argues
• HHS, Pharma Cos. To Offer Streamlined AIDS Patient Assistance
• FDA Says K-V Can't Challenge Its Enforcement Decisions
• Q&A With Choate's Brenda Jarrell
• Fresenius Scoops Up PE-Owned Blood Collection Co.
• Prometheus Unlikely To Sway Fed. Circ.'s Myriad Ruling
• Insurance Co. Says It's Not Liable For Horse Deaths
• Grassley Warns 6 Agencies Of Contractor Data Breach Threat
• Report Faults FDA For Oversight Of Device Cybersecurity
• Q&A With Foley & Lardner's Ybet Villacorta
• Solutia, Pharmacia Take CERCLA Recovery Case To High Court
• UPenn Targets Hospital Over Stalled Immunotherapy Dealings
• Mayo Overlap Between Sections 101 And 102/103 — Not New
• A New View For Pharma Product Liability Litigation
• EU Regulator Backs UniQure's Glybera As First Gene Therapy
• Inventor Kicks Off IP Trial Over Blood Clot Supplement
• Judge Rules Pfizer's Lyrica Patents Are Valid
• Androgel Is FTC's Best Shot At High Court Pay-For-Delay Case
• Drugmaker Taro Rejects Sun Pharma's Latest Buyout Bid
• Judge Won't Cut Weisheng Parent From Vitamin C Cartel Case
• Obesity Drug Approvals Foretell A Less Cautious FDA
• Anti-Painkiller Abuse Bill Might Inflate Cost Of Generics
• EU Court OKs Extended Patents For New Uses Of Old Drugs
• Reps. Seek 'Patient' Clarity In Low-Cost Drug Program
• Bayer Beats Baycol FCA Suit
• Snapshot: The Latest Medical Device FCPA Settlement
• Pharmacy Group Recommends Narrow ACA Drug Coverage
• Q&A With McAndrews' Herb Hart
• Travelers Sues Pfizer For $47M Over Epilepsy Drug
• Biosimilars Makers See Gold Mine In EU Clinical Data
• Genzyme Hit With $50M Judgment In Fabry Treatment IP Fight
• Cephalon Defends Narcolepsy Drug From Generics At Trial
• 11th Circ. Won't Rehear FTC Androgel Pay-For-Delay Case
• Novartis Picks Up Win In Okla. Bone Drug Injury Suit
• FDA Again Delays Nod For Novo Nordisk Long-Acting Insulin
• Somaxon Settles IP Rows With Mylan, Par Over Insomnia Drug
• Q&A With Vinson & Elkins' Ira Schreger
• Abbott Fairly Kept Gay Man Out Of GSK Jury, 9th Circ. Hears
• Reach Of Prometheus Will Come Into Focus In Myriad Ruling
• House Votes To Force OMB To Reveal Sequestration Plans
• Examining Sequenom Prenatal Testing Patent Litigation
• Preempting State Law To Protect Patient Privilege
• FDA OKs Vivus Weight Drug Qsymia After Nod To Rival Arena
• Vt. Owes $2.2M To Health Data Cos. Over Supreme Court Case
• Jones Day Reps Steris In $270M US Endoscopy Buy
• GOP Rep. Wants To Open CBO Numbers To More Scrutiny
• Biosimilars Industry Hopes For Jump-Start From User Fees
• Google Board Sued By Pension Fund Over Online Drug Sales
• Hospira Yanks Cancer Drugs After Finding Flawed Vials
• Shionogi Sues To Block Another Generic Fortamet Challenge
• Q&A With Hogan Lovells' Meredith Manning
• FDA Lawyers Gave Email 'Spying' Green Light, Reports Say
• Device Makers, Doctors Spar Over X-Ray Safety For Kids
• EU Plan To Release More Drug Data Could Spur More US Suits
• SEC Can't Use SOX To Claw Back Bonuses: ArthroCare Execs
• 3rd Circ. Pay-For-Delay Ruling Opens Door To High Court
• FTC OKs Novartis' $1.5B Fougera Buy With Divestitures
• FCA Recoveries On Steep Rise To Record Highs, Report Says
• FDA Approves Gilead Drug To Prevent HIV
• Watson To Pay $1.7M To Exit Idaho AG's Drug Pricing Suit
• Panasonic Accuses CardioNexus Of Obscuring Software's Value
• J&J Beats MDL Over Defective Children's Drugs
• Daiichi Sankyo Sales Reps Drop OT Suit Citing GSK Ruling
• Ex-Sanofi Exec Named Head Of FDA Generics Office
• WilmerHale Reps Thermo Fisher In $925M Buy Of One Lambda
• J&J Heir's $140M Tax Advice Suit Too Late, Proskauer Says
• GSK Finally Lands Human Genome With Upped $3B Offer
• Q&A With Sullivan & Cromwell's Matthew Hurd
• FCA's First-To-File Rule — Mass. Weighs In
• TPG Offers $1.9B For Generic Drug Co. Par Pharmaceutical
• Cephalon Sues To Block Travelers' $17M Actiq Coverage Claim
• Livestock Antibiotic Rules Too Lax, Health Groups Say
• Ala. Court Nixes $78M Price Inflation Verdict Against Sandoz
• Boston Scientific, St. Jude End Data Poaching Dispute
• Sanofi, FedEx Hit Roadblock On Spoiled-Vaccine Settlement
• Q&A With Bingham's Jack Concannon
• Novartis Cancer Unit Escapes Securities Suit
• Lab Won't Explain $82M IP Damages: Ex-Ropes & Gray Atty
• Global Drug Spending To Climb Amid Market Shifts, Report Says
• FDA Aims To Boost Device Makers' Faith In Early Meetings
• CVS Caremark To Halt Coverage For 17 Drugs
• FDA Plans Genome Database For Deadly Foodborne Bacteria
• Bayer Should Ax Calcium Supplement Claims: Ad Regulator
• GSK Tells 3rd Circ. Avandia MDL Cases Can't Be Appealed
• 1st Circ. Kills Investor Suit Over Boston Scientific Sales
• Fed. Circ. Trims Investigation Rules In Vaccine Suits
• GSK Yanks Bid To Combine Tykerb With Roche's Herceptin
• GSK Settlement: Changing The Way Drug Cos. Do Business?
• Q&A With Axinn's Chad Landmon
• FTC Seeks More Info On $5.2B Watson, Actavis Merger
• J&J Vows To Fix Compliance, Quality Issues In Investor Deal
• House Passes 2nd Bill To Repeal Health Care Law
• DOJ Develops A Taste For Deferred Prosecution Deals
• Brain Research Labs Cuts Deal In Class Suit Over Memory Pill
• Hemispherx Says FDA Will Accept Ampligen Analyses
• King & Spalding Hires Ex-Amgen Exec For FDA Practice
• AstraZeneca Wins Seroquel Suit, But Court Punts Warning Issue
• GE Healthcare Recalls Ventilators Over Anesthesia Risks
• How A Texas Plaintiff Found A Way To Causation
• Q&A With Skadden's Douglas Nemec
• UK Court Finds Teva's Copaxone Patent Valid In Mylan Row
• Awaiting The High Court Amgen Decision
• Time Will Tell If FDA Review Update Quickens Drug Approval
• Stryker Recall Undercuts Key Defense For Implant Makers
• Barr Seeks To Use Mensing As Shield In Accutane MDL
• FTC Won't Abandon Pay-For-Delay Offensive, Chief Says
• Masimo Must Face FCA Claims That It Peddled Shoddy Devices
• How They Won It: Lowenstein Breaks Ground With Schering Win
• Orthofix Pays $7.5M To Settle Bribery Cases With SEC, DOJ
• Cubist Hits Hospira With Patent Suit Over Generic Cubicin
• Pharma Co. Shionogi Sues InterMune Over Drug Royalties
• Understanding Mayo V. Prometheus
• Q&A With Knobbe Martens' Joseph Reisman
• Obama Signs FDA User Fee Bill
• Animal Agriculture Groups Blast Report On Antibiotic Use
• FDA Cleared Of Wrongdoing In Generic Xibrom Suit
• FDA Orders Opioid Makers To Fund Abuse Prevention Training
• Dendreon Execs Sued Over Sunny Cancer Drug Sales Forecasts
• HHS OIG Finds Nursing Homes Not Complying With Medicare Regs
• Mass. Loosens Ban On Medical Device Co. Gifts To Doctors
• Employers Will Rush To Comply With ACA Ruling, Report Says
• Mylan Accuses Warner, Mayne Of Plot To Delay Generics
• Hedge Fund Manager Attacked Over Biotech Stock Short Sales
• ACA Loss Ratio Rules Hurt Anti-Fraud Effort, Insurers Say
• Monsanto, Pfizer Try To Revive Enviro Feud With Trucking Co.
• FDA Recalls Maquet Anesthesia Devices Over Ventilation Risk
• Q&A With Quinn Emanuel's Victoria Maroulis
• Legal Challenges, Risks Of Rx Drug Adherence Programs
• Whole Foods Supplements Contain Lead, False Ads Suit Says
• Calif. Judge Won't Halt Sale Of Prenatal Blood Test In IP Row
• Novartis, Merck Hit With RICO Suits Over Drug Copays
• Pfizer To Remove Centrum Breast, Colon Health Claims
• Roche's Breast Cancer Drug Doesn't Make UK Watchdog's Cut
• Allergan Defeats Calif. Doctor's $4M Fraud Suit
• 1st Circ. Stays $26M Drug Injury Award For Mutual's Appeal
• Walgreens, Kroger Sue Pfizer For Delay Of Generic Lipitor
• Endo Targets Generics Makers Over Lidoderm Patch IP
• AstraZeneca Loses Bid To Stretch Seroquel Exclusivity
• Q&A With Baker Botts' Earl Austin
• 4 Drug Cos. Can't Exit FCA Suit Over Medicaid Rebate Prices
• FDA Moves To Crack Down On Unapproved Oxycodone
• Calif. Assembly Advances 2 Health Bills Expanding On ACA
• Sen. Pushes Labeling Rule To Curb Infant Drug Withdrawal
• USPTO Memo Tells Examiners How To Apply Prometheus
• FDA Proposes New Premarket Approval For Some SWD Devices
• Medicare Competitive Bidding Needs Makeover, Study Says
• K-V Pharma Sues FDA Over Exclusivity For Preterm Birth Drug
• Roche Gains FDA Approval For Cytomegalovirus Test
• K&L Gates Hires Nutrition Law Partner For Brussels Office
• Obama Says Health Care Law Is 'Here To Stay'
• Sales Reps Slap Forest Labs With $100M Sex Bias Case
• Pacemaker Electrodes To Switch Approval Processes At FDA
• Robins Kaplan Adds Wilson Sonsini Drug Patent Atty In NY
• Aussie Drug Cos. Will Have To Reveal Doctor Payments
• Jones Day Aids Bayer CropScience In $425M AgraQuest Buy
• A New Prosecutorial Model For Health Care Fraud
• Q&A With Epstein's Kathleen Peterson
• Covance Says It Doesn't Owe $22M In Software License Fees
• Medicare Likely Pays Twice for Hospice Drugs, Audit Says
• House Panel Sees Tax Implications In High Court ACA Ruling
• FDA Unveils Long-Delayed Device Tracking Rule Proposal
• Amylin Shareholder Sues Over $7B Sale To Bristol-Myers
• FDA May Amend Liver Damage Warnings For Acetaminophen
• Roche Must Cough Up $1M Over Scientist Firing, NJ Court Says
• FDA Outlines Approval Process For Medical Detection Systems
• Q&A With Sheppard Mullin's Blaine Templeman
• Sales Reps Say GSK Ruling Doesn't Bar State OT Claims
• Omnicare Asks For Protection From Expected FCA Suit Flood
• How To Use Clinical-Trial Data In Court
• DaVita Inks $55 Million Settlement In Epogen FCA Suit
• Fed. Circ. Nixes Injunction On Lupin's Generic Fortamet
• McKesson Can't Duck Generic Darvocet Liability Claims
• Abbott Again Goes After Sandoz Over Generic Zemplar
• Mylan, Lupin Prevail In Generic-Seasonique Patent Suit
• PolyMedix Hid Drug's Flaws Before $20M Stock Deal, Suit Says
• Hospira Defeats Class Action Over Drug Shortage
• Bristol-Myers, AstraZeneca Team Up On $7B Amylin Deal
• Glaxo Handing Over Record $3B To Settle FCA Claims
• Coca-Cola, GSK, Sherwin-Williams Face CERCLA Suit
• Q&A With Quinn Emanuel's Peter Armenio
• An Overview Of Congress' Sweeping FDA Reforms
• Dewey & LeBoeuf And The 'Unfinished Business' Doctrine